<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2529-850X</journal-id>
<journal-title><![CDATA[Journal of Negative and No Positive Results]]></journal-title>
<abbrev-journal-title><![CDATA[JONNPR]]></abbrev-journal-title>
<issn>2529-850X</issn>
<publisher>
<publisher-name><![CDATA[Research and Science S.L.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2529-850X2023000200003</article-id>
<article-id pub-id-type="doi">10.19230/jonnpr.4806</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Impacto de la hipertensión arterial en el desarrollo de enfermedades cardivosaculares]]></article-title>
<article-title xml:lang="en"><![CDATA[Impact of arterial hypertension on the development of cardiovascular diseases]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Huerta-Valera]]></surname>
<given-names><![CDATA[Natalia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Iruela-Martínez]]></surname>
<given-names><![CDATA[Clara]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tárraga-Marcos]]></surname>
<given-names><![CDATA[Loreto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tárraga-López]]></surname>
<given-names><![CDATA[Pedro J]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Castilla-La Mancha  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Almansa  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad de Castilla la Mancha Departamento de Ciencias Médicas ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>España</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2023</year>
</pub-date>
<volume>8</volume>
<numero>2</numero>
<fpage>542</fpage>
<lpage>563</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2529-850X2023000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2529-850X2023000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2529-850X2023000200003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Las enfermedades cardiovasculares (ECV) son la primera causa de muerte a nivel mundial. Están fuertemente influenciadas por unos factores de riesgo (FR), algunos de ellos modificables con cambios en el estilo de vida. De todos los FR, uno de los más prevalentes en la población es la hipertensión arterial (HTA), definida por unos valores de presión arterial &#8805;140-90mmHg.  Objetivos: Conocer la relación entre la HTA y el resto FR con el desarrollo de las distintas ECV, identificar el umbral idóneo para evitar sobrediagnósticos y sobretratamientos de la HTA, y reconocer la importancia de unos buenos hábitos de vida como prevención.  Resultados y Discusión: En el estudio de FÉLIX-REDONDO et al. se demostró que el FR más influyente en las ECV era la HTA. Sin embargo, esto puede variar según la edad, tal y como observaron VERAREMARTÍNEZ et al. con su estudio, cuya media de edad era de 30 años, y el factor más prevalente fue el tabaco. El control de los hábitos de vida que ayuden a reducir tanto la HTA como el resto de factores, será beneficioso para la prevención primaria y secundaria de ECV. Para evitar un tratamiento demasiado intensivo, es recomendable un enfoque gradual, comenzando con objetivos de prevención para todos los pacientes, independientemente del riesgo, siguiendo con la estratificación del riesgo de ECV y la discusión de los beneficios potenciales del tratamiento con el paciente.  Conclusiones: Las ECV, concretamente la cardiopatía isquémica y las enfermedades cerebrovasculares, son la principal causa de muerte en el mundo, por lo que es muy importante el control de aquellos FR que aceleren la aparición de estas. El más prevalente de ellos, es la presión arterial elevada.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstrac  Introduction: Cardiovascular diseases (CVD) are the leading cause of death worldwide. They are strongly influenced by some risk factors (RF), some of them modifiable with changes in lifestyle. Of all the RFs, one of the most prevalent in the population is arterial hypertension (AHT), defined by blood pressure values &#8805;140-90mmHg.  Objectives: Know the relationship between HTA and the rest RF with the development of different CVDs, identify the ideal threshold to avoid overdiagnosis and overtreatment of HTN, and recognize the importance of good lifestyle habits as prevention.  Results and Discussion: In the study by FÉLIX-REDONDO et al. it was shown that the most influential RF in CVD was AHT. However, this may vary according to age, as observed by VERA-REMARTÍNEZ et al. with his study, whose mean age was 30 years, and the most prevalent factor was tobacco. The control of lifestyle habits that help reduce both hypertension and the rest of the factors will be beneficial for the primary and secondary prevention of CVD. To avoid overly intensive treatment, a stepwise approach is recommended, starting with prevention goals for all patients, regardless of risk, followed by CVD risk stratification and discussion of the potential benefits of treatment with the patient.  Conclusions: CVD, specifically ischemic heart disease and cerebrovascular diseases, are the main cause of death in the world, so it is very important to control those RFs that accelerate their appearance. The most prevalent of them is high blood pressure.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Enfermedades cardiovasculares]]></kwd>
<kwd lng="es"><![CDATA[hipertensión arterial]]></kwd>
<kwd lng="es"><![CDATA[factores de riesgo]]></kwd>
<kwd lng="es"><![CDATA[cardiopatía isquémica]]></kwd>
<kwd lng="es"><![CDATA[enfermedades cerebrovasculares]]></kwd>
<kwd lng="en"><![CDATA[Cardiovascular diseases]]></kwd>
<kwd lng="en"><![CDATA[arterial hypertension]]></kwd>
<kwd lng="en"><![CDATA[risk factor's]]></kwd>
<kwd lng="en"><![CDATA[ischemic heart disease]]></kwd>
<kwd lng="en"><![CDATA[Cerebrovascular diseases]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="">
<source><![CDATA[MORTALIDAD POR ENFERMEDADES CEREBROVASCULARES]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[Genes-dieta-y-enfermedades-cardiovasculares.pdf]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orozco-Beltrán]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Brotons Cuixart]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Alemán Sánchez]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Banegas Banegas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Cebrián-Cuenca]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Gil Guillen]]></surname>
<given-names><![CDATA[VF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones preventivas cardiovasculares. Actualización PAPPS]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2020</year>
<volume>52</volume>
<page-range>5-31</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bragulat]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Hipertensión arterial y riesgo cardiovascular]]></source>
<year></year>
<page-range>6</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Blood pressure and the new ACC/AHA hypertension guidelines]]></article-title>
<source><![CDATA[ScienceDirect]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gijón-Conde]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Gorostidi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Camafort]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Abad-Cardiel]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Martín-Rioboo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Olivas]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de la Sociedad Española de Hipertensión-Liga Española para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial]]></article-title>
<source><![CDATA[Hipertens Riesgo Vasc]]></source>
<year>2018</year>
<volume>35</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>119-29</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gopar-Nieto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ezquerra-Osorio]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Chávez-Gómez]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
<name>
<surname><![CDATA[Manzur-Sandoval]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Raymundo-Martínez]]></surname>
<given-names><![CDATA[GIM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[¿Cómo tratar la hipertensión arterial sistémica? Estrategias de tratamiento actuales]]></article-title>
<source><![CDATA[Arch Cardiol México]]></source>
<year>2021</year>
<volume>91</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>493-9</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<source><![CDATA[Overview | Hypertension in adults: diagnosis and management | Guidance | NICE]]></source>
<year></year>
<publisher-name><![CDATA[NICE]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visseren]]></surname>
<given-names><![CDATA[FLJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mach]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Smulders]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Carballo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Koskinas]]></surname>
<given-names><![CDATA[KC]]></given-names>
</name>
<name>
<surname><![CDATA[Bäck]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2021</year>
<volume>42</volume>
<numero>34</numero>
<issue>34</issue>
<page-range>3227-337</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<collab>Sociedad Europea de Cardiología</collab>
<collab>European Atherosclerosis Society</collab>
<article-title xml:lang=""><![CDATA[Guía ESC/EAS 2019 sobre el tratamiento de las dislipemias: modificación de los lípidos para reducir el riesgo cardiovascular]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2020</year>
<volume>73</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>403.e1-403.e70</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castillo Sánchez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Galera Morcillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez Sánchez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Menárguez Puche]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobrediagnóstico y sobretratamiento en el ámbito cardiovascular: factores de riesgo, no enfermedades]]></article-title>
<source><![CDATA[Aten Primaria]]></source>
<year>2018</year>
<volume>50</volume>
<page-range>20-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-Travieso]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Incidencia actual de la obesidad en las enfermedades cardiovasculares]]></article-title>
<source><![CDATA[Rev CENIC Cienc Biológicas]]></source>
<year>2016</year>
<volume>47</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bryce-Moncloa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alegría-Valdivia]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[San Martin-San Martin]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Obesidad y riesgo de enfermedad cardiovascular]]></article-title>
<source><![CDATA[An Fac Med]]></source>
<year>2017</year>
<volume>78</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>202-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández González]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Figueroa Oliva]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tabaquismo y su relación con las enfermedades cardiovasculares]]></article-title>
<source><![CDATA[Rev Habanera Cienc Médicas]]></source>
<year>2018</year>
<volume>17</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>225-35</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teo]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Rafiq]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular Risk Factors and Prevention: A Perspective From Developing Countries]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2021</year>
<volume>37</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>733-43</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impacto de los factores de riesgo cardiovascular en la población extremeña: aportación de la cohorte HERMEX para una estrategia preventiva]]></article-title>
<source><![CDATA[Elsevier Enhanced Reader]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vera-Remartínez]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lázaro Monge]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Granero Chinesta]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez-Alcón Rodríguez]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Planelles Ramos]]></surname>
<given-names><![CDATA[MV]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular risk factors in young adults of a penitentiary center]]></article-title>
<source><![CDATA[Rev Esp Salud Publica]]></source>
<year>2018</year>
<volume>92</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendoza Alarcón]]></surname>
<given-names><![CDATA[MÁ]]></given-names>
</name>
<name>
<surname><![CDATA[Tejero Mas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Morales-Gabardino]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Buitrago-Ramírez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and degree of control of cardiovascular risk factors in patients with ischemic cardiopathy of an urban health center]]></article-title>
<source><![CDATA[Rev Esp Salud Publica]]></source>
<year>2021</year>
<volume>95</volume>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kotseva]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[De Backer]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Bacquer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Rydén]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Hoes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Grobbee]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry]]></article-title>
<source><![CDATA[Eur J Prev Cardiol]]></source>
<year>2019</year>
<volume>26</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>824-35</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Osorio-Bedoya]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Amariles]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hipertensión arterial en pacientes de edad avanzada: una revisión estructurada]]></article-title>
<source><![CDATA[Rev Colomb Cardiol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>209-21</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gasowski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Staessen]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Celis]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Fagard]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
<name>
<surname><![CDATA[Thijs]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Birkenhäger]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systolic Hypertension in Europe (Syst-Eur) Trial Phase 2: objectives, protocol, and initial progress]]></article-title>
<source><![CDATA[J Hum Hypertens]]></source>
<year>1999</year>
<volume>13</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-45</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García Pastor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[López-Cancio Martínez]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rodríguez-Yáñez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso de Leciñana]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Amaro]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Arenillas]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recomendaciones de la Sociedad Española de Neurología para la prevención del ictus]]></article-title>
<source><![CDATA[Actuación sobre los hábitos de vida y la contaminación atmosférica. Neurología]]></source>
<year>2021</year>
<volume>36</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>377-87</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Keefe]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[DiNicolantonio]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[O'Keefe]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lavie]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alcohol and CV Health: Jekyll and Hyde JCurves]]></article-title>
<source><![CDATA[Prog Cardiovasc Dis]]></source>
<year>2018</year>
<volume>61</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>68-75</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[O'Donnell]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chin]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Rangarajan]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xavier]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2016</year>
<volume>388</volume>
<numero>10046</numero>
<issue>10046</issue>
<page-range>761-75</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Seguimiento de las recomendaciones en prevención secundaria cerebrovascular en atención primaria]]></article-title>
<source><![CDATA[Elsevier Enhanced Reader]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Iadecola]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gottesman]]></surname>
<given-names><![CDATA[RF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Neurovascular and Cognitive Dysfunction in Hypertension]]></article-title>
<source><![CDATA[Circ Res]]></source>
<year>2019</year>
<volume>124</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1025-44</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dong]]></surname>
<given-names><![CDATA[YH]]></given-names>
</name>
<name>
<surname><![CDATA[Lyu]]></surname>
<given-names><![CDATA[PY]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[WH]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hypertension-Induced Cerebral Small Vessel Disease Leading to Cognitive Impairment]]></article-title>
<source><![CDATA[Chin Med J (Engl)]]></source>
<year>2018</year>
<volume>131</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>615-9</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Farah]]></surname>
<given-names><![CDATA[BQ]]></given-names>
</name>
<name>
<surname><![CDATA[Cucato]]></surname>
<given-names><![CDATA[GG]]></given-names>
</name>
<name>
<surname><![CDATA[Andrade-Lima]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Soares]]></surname>
<given-names><![CDATA[AHG]]></given-names>
</name>
<name>
<surname><![CDATA[Wolosker]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Ritti-Dias]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of hypertension on arterial stiffness and cardiac autonomic modulation in patients with peripheral artery disease: a cross-sectional study]]></article-title>
<source><![CDATA[Einstein]]></source>
<year>2021</year>
<volume>19</volume>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skórkowska-Telichowska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kropielnicka]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Buli&#324;ska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pilch]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Wo&#378;niewski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Szuba]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Insufficient modification of atherosclerosis risk factors in PAD patients]]></article-title>
<source><![CDATA[Adv Clin Exp Med Off Organ Wroclaw Med Univ]]></source>
<year>2018</year>
<volume>27</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>819-26</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Beneficios y riesgos potenciales de las metas intensivas en el tratamiento de la hipertensión arterial. Revisión sistemática y metaanálisis de ensayos clínicos]]></article-title>
<source><![CDATA[Archivos de Cardiología de México]]></source>
<year>2020</year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
